Startup Explores Gene-Editing Technology for Embryos
Origin Genomics, a New York City startup, is conducting research into gene-editing technology for human embryos. The company's work focuses on repairing disease-causing genes and assessing the potential benefits against associated risks.
NEW YORK — Origin Genomics, a startup based in New York City, is developing technology designed to edit disease-causing genes within human embryos. The company states its objective is to demonstrate that the potential advantages of its gene-editing method outweigh any associated risks.
Cathy Tie, founder and CEO of Origin Genomics, supervises the replenishment of nutrients for cells used in testing the company's technology. Researchers are employing these cells to evaluate the effectiveness of their gene-repairing techniques.
Related Topics
Article Ratings
How do you feel about this story?
National Desk
Sign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!